Trial Profile
An open label study to evaluate the correlation between serum infliximab level and loss of response (LOR) to treatment in patients with Crohn's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 08 Dec 2015 New trial record